拉布立酶

Rasburicase

Abstract

No information is available on the clinical use of rasburicase during breastfeeding. Because it is a large protein molecule with a molecular weight of about 34,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably partly destroyed in the infant's gastrointestinal tract.[1,2] However, the manufacturer recommends that breastfeeding be discontinued during rasburicase therapy and for 2 weeks after the final dose. An alternate drug can be considered.

摘要

关于哺乳期使用拉布立酶的临床信息尚无可用资料。由于它是一种分子量约为34,000道尔顿的大蛋白质分子，乳汁中的含量可能非常低，而且由于它可能在婴儿胃肠道中部分被破坏，不太可能被吸收。[1,2] 然而，制造商建议在拉布立酶治疗期间及最后一剂后2周内停止母乳喂养。可以考虑使用替代药物。